SCD inhibition preferentially eradicates AML displaying high de novo fatty acid desaturation and synergizes with chemotherapy

Vilma Dembitz(University of Zagreb), Paolo Gallipoli(Wellcome/MRC Cambridge Stem Cell Institute), Sophie C. James(Queen Mary University of London), Keith Woodley(Bank of England), Jan Jacob Schuringa(University Medical Center Groningen), Findlay Bewicke‐Copley(Queen Mary University of London), Andrew J. Finch(Queen Mary University of London), Juerg Schwaller(University Hospital of Basel), Emeline Boët(Centre National de la Recherche Scientifique), Lydia M. Wang(Institute of Cancer Research), Pedro R. Cutillas(Consejo Superior de Investigaciones Científicas), Richard Burt(The Francis Crick Institute), Alex von Kriegsheim(Edinburgh Cancer Research), Jozef Durko(Queen Mary University of London), Hannah Lawson(University of London), Ana Rio‐Machín(Queen Mary University of London), Jean‐Emmanuel Sarry(Inserm), Lori Hazlehurst(West Virginia University), Kamil R. Kranc(Institute of Cancer Research), Joana Campos(Queen Mary University of London), Lieve Oudejans(University Medical Center Groningen), Pedro Casado(Queen Mary University of London), Bela Patel(Queen Mary University of London), Diego A. Pereira‐Martins(University Medical Center Groningen), Aoife M. S. Magee(Queen Mary University of London), Céline Philippe(Queen Mary University of London), Kevin Rouault‐Pierre(Queen Mary University of London), Jude Fitzgibbon(Queen Mary University of London), Barrie Peck(Cancer Research Center), Giovanny Rodriguez Blanco(Edinburgh College), Samantha Atkinson(The Francis Crick Institute), John A. Copland(Jacksonville College), Jérôme Tamburini(Centre National de la Recherche Scientifique), Michael Austin(Queen Mary University of London), Mariia Yuneva(The Francis Crick Institute)
bioRxiv (Cold Spring Harbor Laboratory)
August 5, 2023
Cited by 1


Related Papers